Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

被引:0
|
作者
Zhang, Xinyu [1 ,2 ,3 ]
Cao, Chao [1 ,2 ]
Zheng, Fei [1 ,2 ]
Liu, Chang [1 ,2 ]
Tian, Xiuqing [1 ,2 ,3 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, 6699 Qingdao Rd, Jinan City 250117, Peoples R China
关键词
GLP-1; RAs; Cardiovascular; Type; 2; diabetes; Ischemic cardiomyopathy; Diabetic cardiomyopathy; Heart failure; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELL; IMPROVING MITOCHONDRIAL-FUNCTION; LEFT-VENTRICULAR PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; INSULIN-SECRETION; EJECTION FRACTION; CONSCIOUS DOGS; BLOOD-PRESSURE;
D O I
10.1007/s10557-025-07670-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundGlucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.ObjectiveThis review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential.MethodsA comprehensive review was carried out through literature research.Results and DiscussionIn pancreatic beta-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of beta-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients.ConclusionGLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
    Ma, Xiaoxuan
    Liu, Zhenghong
    Ilyas, Iqra
    Little, Peter J.
    Kamato, Danielle
    Sahebka, Amirhossein
    Chen, Zhengfang
    Luo, Sihui
    Zheng, Xueying
    Weng, Jianping
    Xu, Suowen
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (08): : 2050 - 2068
  • [2] GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
    Isabel del Olmo-Garcia, Maria
    Francisco Merino-Torres, Juan
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [3] Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes
    Inzucchi, Silvio E.
    Arai, Andrew E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (06) : 558 - 560
  • [4] Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
    Liu, Qiyuan Keith
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [5] GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
    Mundil, Dhanwantee
    Cameron-Vendrig, Alison
    Husain, Mansoor
    DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (02): : 95 - 108
  • [6] Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
    Verge, Danilo
    Lopez, Ximena
    CURRENT DIABETES REVIEWS, 2010, 6 (04) : 191 - 200
  • [7] Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management
    Delrue, Charlotte
    Speeckaert, Marijn M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [8] Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
    Nowak, Klaudia
    Lupina, Krzysztof
    Romac, Anna
    Kalisz, Aleksandra
    Ilkiewicz, Lucja
    Janczura, Jakub
    ANNALS OF PHARMACOTHERAPY, 2025,
  • [9] The Cardiovascular Effects of GLP-1 Receptor Agonists
    Okerson, Theodore
    Chilton, Robert J.
    CARDIOVASCULAR THERAPEUTICS, 2012, 30 (03) : e146 - e155
  • [10] Cardiovascular safety and GLP-1 receptor agonists
    Carty, David M.
    Drummond, Russell
    Fisher, Miles
    PRACTICAL DIABETES, 2013, 30 (06) : 242 - 245